Navigation Links
Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
Date:8/1/2008

NEW BRUNSWICK, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that Bayer CropScience has successfully completed the first R&D milestone related to Bayer's use of Senesco's technology in Brassica oilseeds.

Senesco's proprietary gene technology was licensed to Bayer CropScience in November 2006 to enhance Canola yields in Bayer's InVigor(R) canola hybrids and future hybrid's business internationally. Upon completion of this milestone, Senesco received an undisclosed payment from Bayer.

"We are pleased to arrive at this initial R&D milestone with Bayer CropScience," said Bruce Galton, President and CEO of Senesco. "We believe that our gene technology has broad application to both food and non-food crops."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to raise additional capital to fund its research and development efforts; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
2. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
3. Senesco Technologies to Present at BIO 2008 Business Forum
4. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
5. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
6. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
8. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
9. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
10. Local officials move toward monitoring nanotechnologies
11. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... Manitoba (PRWEB) , ... April 27, 2016 , ... ... released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) ... better understanding disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI ...
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
Breaking Biology Technology:
(Date:3/2/2016)... , March 2, 2016 ... the addition of the  "Global Biometrics Market ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global ... grow at a CAGR of around 27% ... ) has announced the addition of the  ...
(Date:3/1/2016)... 2016 http://www.researchandmarkets.com/research/ghsgdt/global_biometric ... the  "Global Biometric Access Control Systems ... offering. --> http://www.researchandmarkets.com/research/ghsgdt/global_biometric ) ... "Global Biometric Access Control Systems Market ... --> Research and Markets ( ...
(Date:3/1/2016)... and SAN FRANCISCO , March ... HYPR Corp. and BitGo, Inc. extends biometric authentication to ... and private keys. Bitcoin transactions ... billion per month in digital assets with over 10,000 ... for any startup. HYPR enables enterprises to keep encrypted ...
Breaking Biology News(10 mins):